Romosozumab
Performance & EnduranceSclerostin inhibitor monoclonal antibody for osteoporosis, both builds and preserves bone.
Key Benefits
- ✓Builds and preserves bone simultaneously
- ✓Rapid BMD increases
- ✓High-risk osteoporosis
- ✓12-month treatment
- ✓Dual mechanism
Dosing Information
Detailed Protocol
Administered as two subcutaneous injections (105mg each, 210mg total) once monthly for 12 consecutive months maximum. Must be followed by antiresorptive. Medical supervision.
About Romosozumab
Romosozumab (Evenity) is a humanized monoclonal antibody that inhibits sclerostin. It has dual effect: increases bone formation and decreases bone resorption. FDA-approved for postmenopausal osteoporosis at high fracture risk. Limited to 12 monthly doses.
Research Notes
FDA-approved in 2019 for osteoporosis. Unique dual mechanism provides rapid BMD gains. Treatment limited to 12 months. Black box warning for cardiovascular events. Must transition to antiresorptive.
Potential Side Effects
- •Injection site reactions
- •Arthralgia
- •Headache
- •Possible increased cardiovascular risk
- •12-month limit
- •Must transition to antiresorptive
Always consult with a healthcare professional before starting any peptide therapy.